This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Lipids and Lipid Disorders  • Alert me on articles by topic

Clinical Challenges for More Widespread Therapy of Lipids to Treat and Prevent Coronary Heart Disease

Arch Intern Med. 2002;162:2033-2036.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE RECENTLY published National Cholesterol Education Program (NCEP) III guidelines¹ present many new clinical challenges to health care providers and their patients. These guidelines recommend stricter target lipid levels as well as a broader approach to risk assessment in an effort to reduce premature death and disability from coronary heart disease (CHD) and stroke. Many more patients, especially in primary prevention, are candidates to improve their lipid profiles under the new guidelines. It has been estimated that, as a direct result of the new NCEP III guidelines, the number of US adults eligible for lipid modification has increased from 52 million to 65 million for therapeutic lifestyle changes, including diet, and almost 3-fold, from about 13 million to 36 million, for drug therapy (Figure 1).² This report identifies and characterizes the untreated patients who would benefit from lipid modification and summarizes the efficacy, safety, and cost profiles of . . . [Full Text of this Article]

GLOBAL RISK ASSESSMENT


CRITERIA AND GOALS FOR LIPID MODIFICATION

SCREENING AND TREATMENT

THERAPEUTIC LIFESTYLE CHANGES

DRUG THERAPIES

RELATIVE BENEFITS, RISKS, AND COSTS OF VARIOUS STATINS

THE NEED FOR CLINICAL JUDGMENT

CONCLUSIONS

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Aspirin to Reduce Risks of Cardiovascular Disease in Patients With Diabetes: Clinical and research challenges
Hennekens et al.
Diabetes Care 2004;27:2752-2754.
FULL TEXT  

The National Cholesterol Education Program Diet vs a Diet Lower in Carbohydrates and Higher in Protein and Monounsaturated Fat: A Randomized Trial
Aude et al.
Arch Intern Med 2004;164:2141-2146.
ABSTRACT | FULL TEXT  

Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study
Serebruany et al.
Arch Intern Med 2004;164:2051-2057.
ABSTRACT | FULL TEXT  

Randomized Trials of Vitamin E in the Treatment and Prevention of Cardiovascular Disease
Eidelman et al.
Arch Intern Med 2004;164:1552-1556.
ABSTRACT | FULL TEXT  

Hypothesis: Atorvastatin Has Pleiotropic Effects that Translate into Early Clinical Benefits on Cardiovascular Disease
Novela and Hennekens
J CARDIOVASC PHARMACOL THER 2004;9:61-63.
ABSTRACT  

Global risk assessment for cardiovascular disease and astute clinical judgement
Hennekens and D'Agostino
Eur Heart J 2003;24:1899-1900.
FULL TEXT  

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease
Eidelman et al.
Arch Intern Med 2003;163:2006-2010.
ABSTRACT | FULL TEXT  

Are Antiplatelet Effects of Clopidogrel Inhibited by Atorvastatin?: A Research Question Formulated but Not Yet Adequately Tested
Serebruany et al.
Circulation 2003;107:1568-1569.
FULL TEXT